TABLE 2.
Ongoing clinical trials for P‐selectin inhibitors (modified from clinicaltrials.gov)
| Ongoing: ClinicalTrials.Gov study numbers for Inclacumab | |||
| VOC in SCD | NCT04935879 | Phase 3 | Global blood therapeutics |
| Recurrent VOC in SCD | NCT04927247 | Phase 3 | Global blood therapeutics |
| Ongoing: ClinicalTrials.Gov study numbers for Crizanlizumab | |||
| COVID−19 | NCT04505774 | Phase 4 | University of Pittsburgh |
| Myelofibrosis | NCT04097821 | Phase 1/2 | Novartis |
| Priapism | NCT03938454 | Phase 2 | Novartis |
| RVCL | NCT04611880 | Phase 2 | Washington University |
| SCD (Pediatrics) | NCT03474965 | Phase 2 | Novartis |
| SCD | NCT04053764 | Phase 2 | Novartis |
| SCD | NCT03264989 | Phase 2 | Novartis |
| SCD | NCT03814746 | Phase 3 | Novartis |
| SCD | NCT04657822 | Phase 4 | Novartis |
| SCD | NCT04662931 | Phase 4 | Novartis |